



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

February 09, 2026

To,

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001  
Scrip Code: 543434

National Stock Exchange of India Limited  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex  
Bandra (E), Mumbai - 400 051  
NSE Symbol: SUPRIYA

Dear Sir (s),

**Sub: Outcome of Board Meeting held on February 09, 2026**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Monday, February 09, 2026, inter-alia considered and approved the following:

**1. Unaudited Financial Results:**

The Unaudited Financial Results for the Quarter and nine months ended December 31, 2025. A copy of the same is enclosed along with the Limited Review Report of the Statutory Auditors thereon in terms of SEBI (LODR) Regulations, 2015.

**2. Change in Directorate – Appointment/ Re-appointment of Independent Directors:**

- a) Re-appointment of Dr. Neelam Yashpal Arora (DIN: 01603068) as Non-Executive Independent Woman Director of the Company for second term of 5 consecutive years with effect from March 25, 2026, to March 24, 2031, subject to approval of the shareholders of the Company.
- b) Appointment of Mr. Manish Panchal (DIN: 08431492) as Additional Independent Director of the Company with effect from February 09, 2026, to February 08, 2031, subject to approval of shareholders of the Company.
- c) Appointment of Mr. Kothandaraman Hari (DIN: 08901674) as Additional Independent Director of the Company with effect from February 09, 2026, to February 08, 2031, subject to approval of shareholders of the Company.

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.

Tel: +91 22 40332727 / 66942507      Fax : +91 22 26860011      GSTIN: 27AALCS8686A1ZX

CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299      Fax: +91 2356 272178      E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

**3. Reconstitution of Committees of the Board:**

**Audit Committee**

- |   |                                 |          |
|---|---------------------------------|----------|
| 1 | Mr. Hari K.                     | Chairman |
| 2 | Dr. Ganapati Dadasaheb<br>Yadav | Member   |
| 3 | Dr. Satish Waman Wagh           | Member   |
| 4 | Mr. Manish Panchal              | Member   |

**Nomination and Remuneration Committee**

- |   |                           |          |
|---|---------------------------|----------|
| 1 | Mr. Hari K.               | Chairman |
| 2 | Dr. Sunil Subhash Bhagwat | Member   |
| 3 | Mr. Manish Panchal        | Member   |

**Stakeholders' Relationship Committee**

- |   |                        |          |
|---|------------------------|----------|
| 1 | Mr. Manish Panchal     | Chairman |
| 2 | Dr. Saloni Satish Wagh | Member   |
| 3 | Dr. Satish Waman Wagh  | Member   |

The details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith.

The Meeting of the Board of Directors of the Company commenced at 03:00 p.m. and concluded at 05.00 p.m.

Kindly take the above information on your records.

Thanking you,

Yours faithfully,

**For Supriya Lifescience Limited**

**Prachi Sathe  
Company Secretary & Compliance Officer**

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507      Fax : +91 22 26860011      GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299      Fax: +91 2356 272178      E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

**Annexure A**

**1) Appointment of Dr. Neelam Yashpal Arora (DIN: 01603068) as Woman Independent Director for second consecutive term of five years:**

<b>Particulars</b>	<b>Dr. Neelam Yashpal Arora (DIN: 01603068)</b>
Reason for Change viz. appointment, reappointment, resignation, removal, death or otherwise	Re-appointed as Woman Independent Director of the Company.
Date of Appointment/ reappointment /cessation (as applicable) and term of appointment /reappointment	Re-appointment of Dr. Neelam Arora as Non-Executive Independent Director of the Company with effect from March 25, 2026.
Term of re-appointment	Dr. Arora has been re-appointed for a period of 5 (five) consecutive years from March 25, 2026, to March 24, 2031, subject to approval of the shareholders.
Brief Profile (in case of appointment)	Dr. Neelam Yashpal Arora is Woman Independent Director of our Company. She holds a bachelor's degree in commerce from the University of Mumbai, a master's degree in commerce from SNDT College of Arts & Smt. C.B. College of Commerce and Economics for Women, Shreemati Nathibai Damodar Thackersey Woman's University, Mumbai, a bachelor's and a master's degree in law from the University of Mumbai and a PhD in commerce from University of Mumbai. She has over 31 years of teaching and around 10 years of administrative experience in education field.  Dr. Arora is of a professional acumen with vide experience in the fields of education, commerce, taxation, economics and law and is an asset to the Company.
Disclosure of relationship between Directors (in case of appointment of	Dr. Arora is not related to any Director or Key Managerial Personnel of the Company.

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
 Tel: +91 22 40332727 / 66942507      Fax : +91 22 26860011      GSTIN: 27AALCS8686A1ZX  
 CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
 Tel: +91 2356 272299      Fax: +91 2356 272178      E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

Directors)	
Affirmation	As per declaration submitted to the Company, Dr. Arora has confirmed that she is not debarred from holding office of director by virtue of any SEBI order or any other such authority

**2) Appointment of Mr. Manish Panchal (DIN: 08431492) as Additional Independent Director of the Company:**

<b>Particulars</b>	<b>Mr. Manish Panchal (DIN: 08431492)</b>
Reason for Change viz. appointment, reappointment, resignation, removal, death or otherwise	Appointed as Additional Independent Director of the Company.
Date of Appointment/ reappointment /cessation (as applicable) and term of appointment /reappointment	February 09, 2026
Term of Appointment	Appointed for a period of 5 years subject to approval of the shareholders by way of special resolution.
Brief Profile (in case of appointment)	Mr. Manish Panchal is a Business Leader with more than 32 years of cross industry experience ranging in various sector like Chemicals & New Energy, Logistics, Pharmaceutical, Medical Devices and Healthcare. His industry experience lies in various functional areas including Strategy & Innovation, Operational Excellence, Business Development, Sales & Marketing, P&L Management.  He is active in Investment Banking Domain, supporting companies to raise the Growth Fund through VC / PE or Public Offers (IPOs). He also advises companies to grow exponentially (5X in 5 years) by aligning businesses with Unique 5 P's framework (Profits /Products / Processes / People / Performance).

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
 Tel: +91 22 40332727 / 66942507      Fax : +91 22 26860011      GSTIN: 27AALCS8686A1ZX  
 CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
 Tel: +91 2356 272299      Fax: +91 2356 272178      E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

	Mr. Panchal is a member of various Companies including IL & FS AMC Limited, Nesco Limited, Patil Group, Vashi Integrated Solutions, Aaji Care Home Health Services Private Limited, Aaji Care Sevak Foundation, Arujiva, FICCI, Tata Strategic Management Group, Abbott Laboratories.
Disclosure of relationship between Directors (in case of appointment of Directors)	Mr. Manish Panchal is not related to any Director or Key Managerial Personnel of the Company.
Affirmation	As per declaration submitted to the Company, Mr. Panchal has confirmed that he is not debarred from holding office of director by virtue of any SEBI order or any other such authority

**3) Appointment of Mr. Kothandaraman Hari (DIN: 08901674) as Additional Independent Director of the Company:**

Particulars	Mr. Kothandaraman Hari (DIN: 08901674)
Reason for Change viz. appointment, reappointment, resignation, removal, death or otherwise	Appointed as Additional Independent Director of the Company.
Date of Appointment/ reappointment /cessation (as applicable) and term of appointment /reappointment	February 09, 2026
Term of Appointment	Appointed for a period of 5 years subject to approval of the shareholders by way of special resolution.
Brief Profile (in case of appointment)	Hari K is a capital markets professional with over 28 years of experience, having contributed to the National Stock Exchange of India's (NSE) ascent as a global leader. As Executive Vice President at NSE, he led strategic initiatives across multiple asset classes, including Equities, Debt, Derivatives, and Listings,

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
 Tel: +91 22 40332727 / 66942507      Fax : +91 22 26860011      GSTIN: 27AALCS8686A1ZX  
 CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
 Tel: +91 2356 272299      Fax: +91 2356 272178      E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

	<p>while shaping policy, regulatory frameworks, and business expansion efforts. He is a founder of Onspin Consultants LLP, based in Mumbai.</p> <p>He has served on the boards of NSE Academy, NSE Cogencis, and the India International Bullion Exchange, contributing to governance, strategic planning, and risk oversight. His deep experience in both regulatory and entrepreneurial roles enables him to offer a unique blend of institutional expertise and agile execution.</p>
Disclosure of relationship between Directors (in case of appointment of Directors)	Mr. Hari is not related to any Director or Key Managerial Personnel of the Company.
Affirmation	As per declaration submitted to the Company, Mr. Hari has confirmed that he is not debarred from holding office of director by virtue of any SEBI order or any other such authority

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507      Fax : +91 22 26860011      GSTIN: 27AAC8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299      Fax: +91 2356 272178      E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**

**KAKARIA AND ASSOCIATES LLP**

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.

AMAR J. BHANUSHALI B.Com., D.T.M., F.C.A.

VINAYAK P. BAFANA B.Com., F.C.A.

YOUR REF. :

OUR REF. :


**Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To,

Board of Directors of Supriya Lifescience Limited,

1. We have reviewed the accompanying statement of unaudited financial results of Supriya Lifescience Limited ("the Company") for the quarter ended 31<sup>st</sup> December 2025, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations")
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,  
Mumbai - 400 053 Tel: 022 26744670. Email: [mumbai@kakariaassociates.com](mailto:mumbai@kakariaassociates.com),  
Website: [www.kakariaassociates.com](http://www.kakariaassociates.com)




matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14<sup>th</sup> October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For,  
Kakaria and Associates LLP  
Chartered Accountants.  
FRN: 104558W/ W100601

  
CA. Ujwal K. Kakaria  
Partner  
Membership No. - 035416  
Place: - Mumbai  
Date: - 9<sup>th</sup> February, 2026  
UDIN: - 26035416GRBOFW8463





SUPRIYA LIFESCIENCE LIMITED  
CIN No: L51900MH2008PLC180452

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: L51900MH2008PLC180452  
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

(₹ In million)

Part I - Statement of Standalone Unaudited Financial Results for the Quarter and Nine month ended 31st December, 2025

Sr.No.	Particulars	Quarter ended 31-12-2025 Unaudited	Quarter ended 30-09-2025 Unaudited	Quarter ended 31-12-2024 Unaudited	Nine month ended 31-12-2025 Unaudited	Nine month ended 31-12-2024 Unaudited	Year ended 31-03-2025 Audited
<b>Income</b>							
I	Revenue from Operations	2,064.40	1,998.33	1,856.48	5,513.47	5,123.76	6,964.85
II	Other Income	26.11	27.25	20.98	80.10	68.40	98.15
III	<b>Total Income</b>	<b>2,090.51</b>	<b>2,025.58</b>	<b>1,877.45</b>	<b>5,593.57</b>	<b>5,192.16</b>	<b>7,063.00</b>
2	<b>Expenses</b>						
a)	Cost of Materials Consumed	772.98	606.83	135.97	1,817.57	1,309.05	2,324.36
b)	Purchase of Stock in Trade	-	-	-	-	-	-
c)	Change in inventories of finished goods, work in progress & stock in trade.	(160.98)	(49.53)	481.82	(330.55)	254.46	(212.59)
d.	Employee benefit expenses	246.94	244.81	197.72	718.63	595.42	805.19
e.	Finance Cost	4.94	4.15	5.07	14.21	12.68	16.86
f.	Depreciation & amortisation expense	68.21	66.39	49.64	199.11	143.63	204.44
g.	Other expenditure	484.64	469.75	381.44	1,343.52	1,032.72	1,439.93
IV	<b>Total Expenses</b>	<b>1,416.73</b>	<b>1,342.40</b>	<b>1,251.65</b>	<b>3,762.49</b>	<b>3,347.96</b>	<b>4,578.19</b>
V	Profit/(loss) before Exceptional Items & Tax (III-IV)	673.78	683.18	625.80	1,831.08	1,844.20	2,484.80
VI	Exceptional Items	(4.58)	-	-	(4.58)	-	-
VII	<b>Profit/(loss) before Tax (V-VI)</b>	<b>669.20</b>	<b>683.18</b>	<b>625.80</b>	<b>1,826.50</b>	<b>1,844.20</b>	<b>2,484.80</b>
VIII	<b>Tax Expense</b>						
a)	Current Tax	153.24	151.58	137.72	410.17	438.85	566.57
b)	Deferred Tax	19.21	27.33	20.25	67.41	29.58	38.66
IX	<b>Profit/(Loss) for the period from Continuing Operations (VII-VII)</b>	<b>496.75</b>	<b>504.27</b>	<b>467.83</b>	<b>1,348.92</b>	<b>1,375.76</b>	<b>1,879.58</b>
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-	-
XIII	<b>Profit/(Loss) for the period (IX+XII)</b>	<b>496.75</b>	<b>504.27</b>	<b>467.83</b>	<b>1,348.92</b>	<b>1,375.76</b>	<b>1,879.58</b>
XIV	<b>Other Comprehensive Income</b>						
A (i)	Items that will not be reclassified to profit or loss	0.54	0.45	0.81	(1.88)	(2.83)	(1.67)
(ii)	Income Tax relating to items that will not be reclassified to profit or loss	(0.14)	(0.11)	(0.20)	0.47	0.71	0.42
B (i)	Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii)	Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	<b>Total Comprehensive Income for the period (XIII+XIV)</b>	<b>497.15</b>	<b>504.61</b>	<b>468.43</b>	<b>1,347.51</b>	<b>1,373.65</b>	<b>1,878.33</b>
XVI	Earnings per equity Share (for continuing operation):						
(1)	Basic (In ₹)	6.17	6.27	5.82	16.76	17.07	23.35
(2)	Diluted (In ₹)	6.17	6.27	5.82	16.76	17.07	23.35
XVII	Earnings per equity Share (for discontinued operation):						
(1)	Basic (In ₹)	-	-	-	-	-	-
(2)	Diluted (In ₹)	-	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):						
(1)	Basic (In ₹)	6.17	6.27	5.82	16.76	17.07	23.35
(2)	Diluted (In ₹)	6.17	6.27	5.82	16.76	17.07	23.35




See accompanying notes to the financial statements:

Notes:-

1. The unaudited standalone financial results of the Company for the quarter and nine month ended December 31, 2025 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.
2. The above unaudited standalone financial results of the Company for the quarter and nine month ended December 31, 2025 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on February 09, 2026.
3. The Company has adopted Ind AS 16 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
4. The company does not have any subsidiary/associate/joint venture company as on December 31, 2025.
5. Effective November 21, 2025, the Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The company has identified impact of New Labour Codes amounting to Rs. 4.58 Million and presented such amount under exceptional item. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact of these will be accounted in accordance with applicable accounting standards as and when these developments are known and applicable.
6. The figures of the previous periods have been regrouped wherever necessary to confirm to the current period presentation.

For Supriya Lifescience Limited

  
Dr. Satish Waman Wagh  
Chairman and Executive Director.  
DIN: 01456982



Place :- Mumbai  
Date :- February 09, 2026